Pharmaceutical Associates
Last updated Jun 6, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
73%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Antiemetic
Highest priority development: FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for PHARM ASSOC.; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 73%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 16FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)
Oncology · Antiemetic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LEVOCETIRIZINE DIHYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Pharmaceutical Associates right now?
- Which regulatory precedents should Pharmaceutical Associates monitor in Oncology and Antiemetic?
- How does Regulatory Developments in Oncology compare to the nearest competitive programs?
- What signals require immediate investigation for Pharmaceutical Associates?
- Summarize the strategic implications of recent developments for Pharmaceutical Associates.
- Where is the greatest uncertainty in Pharmaceutical Associates's competitive positioning?